Health News Releases

  • Today February 18
June 03, 2016 11:50
Boehringer Ingelheim launches ambitious ELUXA trial programme to broadly investigate promising lung cancer compound olmutinib
Boehringer Ingelheim has initiated the ELUXA trial programme, designed to further investigate the therapeutic potential of olmutinib* (BI 1482694 / HM61713), a novel third-generation, epidermal growth
June 02, 2016 16:55
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for th
June 01, 2016 19:00
Worldwide Innovative Networking (WIN) in Personalized Cancer Medicine is Very Proud to Announce That Institut Curie, France Has Joined Its Consortium
“We are very proud to welcome Institut Curie to WIN,” said Dr. John Mendelsohn, Chairman of WIN and Director of the Khalifa Institute for Personalized Cancer Therapy and past President of MD Anderson
May 31, 2016 18:45
Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis
Boehringer Ingelheim and Inventiva, a French biopharmaceutical company specialised in the development of innovative therapies for fibrosis, oncology and orphan diseases, announced today, a new multi-y
May 30, 2016 13:55
Samsung Bioepis Becomes First to Obtain European Commission Approval for Second Anti-TNF-α Biosimilar with Flixabi®
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Flixabi® - a biosimilar version of Remicade® (infliximab), also known as SB2 - for the treatment of rheumatoid arth
May 30, 2016 11:40
Takeda Provides Update on EU Marketing Authorization Application for NINLARO® (ixazomib) in Relapsed/Refractory Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion, recom
May 27, 2016 14:20
Masimo to Showcase Next Generation SedLine® Brain Function Monitor at 2016 Euroanaesthesia Congress
Masimo (NASDAQ: MASI) announced today the CE mark and scheduled full market release of Next Generation SedLine® Brain Function Monitoring technology at the European Society of Anaesthesiology’s (ESA)
May 27, 2016 13:05
3 out of 4 people with symptomatic asthma report reduced productivity at work
Not for distribution to UK/US/Canadian media Results were released today by Boehringer Ingelheim from an international survey, providing new insight into the negative impact of persistent asthma sy
May 26, 2016 16:40
Sumitomo Heavy Industries Announces Samsung Medical Center Starts Proton Therapy
Sumitomo Heavy Industries, Ltd. (TOKYO:6302) (“SHI”) today announces that Samsung Medical Center (“SMC”) in Seoul, Korea has commenced proton therapy*1 and the opening ceremony was held on May 3, 2016
May 25, 2016 15:30
Herbalife Sponsors Four National Olympic Committees at Rio 2016 Olympics and Paralympic Games
Global nutrition company Herbalife (NYSE: HLF) announced today it will be the official sponsor of the Costa Rican, Israeli, Italian and Vietnam National Olympic Committees all traveling to the Rio 201
May 25, 2016 11:00
IL-23 inhibitor risankizumab induces remission in Phase II study in patients with moderate-to-severe Crohn’s disease
Results were presented today from a proof-of-concept, Phase II, randomized, placebo-controlled study (NCT02031276) in Crohn’s disease with investigational biologic, risankizumab (formerly BI 655066),
May 24, 2016 15:15
Ferring Pharmaceuticals: World Bedwetting Day 2016 - New Evidence Confirms the Impact of Bedwetting on Children’s Daytime Functioning
World Bedwetting Day 2016 is marked today by the World Bedwetting Day Steering Committee, a new working group led by the International Children’s Continence Society (ICCS) and the European Society for
May 24, 2016 10:10
Samsung Bioepis' Biologics License Application for SB2 Infliximab Biosimilar Accepted by U.S. Food and Drug Administration
Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) for SB2, a biosimilar candidate ref
May 23, 2016 18:00
Scotland’s Patient Safety Programme Makes a Commitment to the Patient Safety Movement Foundation
The Patient Safety Movement Foundation (PSMF) announced today a commitment from Scotland’s national patient safety initiative, the Scottish Patient Safety Programme (SPSP). Launched in 2008, the SP
May 23, 2016 17:50
Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing
Boehringer Ingelheim and BioMed X announced today that they have established a new research team of outstanding scientists from around the world that will conduct research to identify novel approaches
May 20, 2016 14:00
Work It Out! Symbiotics® a Real Player in Muscle Recovery and Gut Health
Symbiotics®, a Naturade product, is the premier source of gastrointestinal health (GI) products that promote normal gut health and a healthy immune system which may enhance stamina and normal lean mus
May 18, 2016 12:05
South Korea is first to approve next generation lung cancer treatment olmutinib (BI 1482694 / HM61713)
Olmutinib* (BI 1482694 / HM61713) has been approved in South Korea for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non
May 17, 2016 17:30
New Presentations at ATS 2016 Reinforce OFEV® (nintedanib) Efficacy, Safety and Tolerability Across Broad Range of Patients with IPF
New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF).
May 17, 2016 11:00
GNT Pharma Receives IND Approval for Phase II Clinical Trial for Stroke Patients with Endovascular Treatment with First in Class Multi-Target Neuroprotection Drug Neu2000
GNT Pharma (“GNTP”) announced that the Korea Ministry of Food and Drug Safety has approved the company's Investigational New Drug (IND) application to initiate a Phase II clinical study of Neu2000 in
Herbalife members take steps towards inspiring healthy active living.(Photo: Business Wire)
May 16, 2016 14:14
Herbalife Rallies its Network to Inspire Healthy Active Living in Bid to Combat Obesity in Asia Pacific
Herbalife, a global nutrition company, has concluded its annual Asia Pacific training event - Extravaganza 2016 - held in Singapore from May 13-15. This year’s event saw Herbalife rally 10,000 of its
May 13, 2016 10:50
Takeda Appoints New Chief Financial Officer, James Kehoe
Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502) today announced the appointment of James Kehoe as Takeda’s new Chief Financial Officer and Corporate Officer, effective on June 15, 2016.
May 12, 2016 14:15
Pradaxa®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain
Boehringer Ingelheim will undertake the first prospective, randomised controlled study of a non-vitamin K antagonist oral anticoagulant (NOAC) in patients with blood clots in the veins or venous sinus
May 11, 2016 18:35
Boehringer Ingelheim: Nine out of 10 AF patients are concerned about stroke and many want to be part of OAC treatment decisions, new international survey shows
Nine out of 10 patients with atrial fibrillation (AF) surveyed were concerned about the risk of a stroke.[1] Oral anticoagulant (OAC) treatments are usually prescribed to reduce this risk3 and the vas
May 11, 2016 18:25
Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe
Incyte Corporation (Nasdaq:INCY) and ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA) today announced the entry into a definitive agreement for Incyte to acquire ARIAD’s European operations. At the close of
May 11, 2016 13:15
JHL Biotech Opens Innovative Biosimilars Manufacturing Facility in China
JHL Biotech (JHL), a biopharmaceutical company, opened the world’s first KUBio™ biopharmaceutical manufacturing facility with single-use bioprocessing technology at a ribbon-cutting ceremony in Wuhan,
25 per page50 per page75 per page100 per page